Tempus AI (NASDAQ:TEM) CEO Sells $8,500,362.50 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $51.13, for a total value of $8,500,362.50. Following the completion of the transaction, the chief executive officer owned 8,841,783 shares in the company, valued at $452,080,364.79. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

TEM opened at $55.02 on Friday. The business’s 50-day moving average is $50.65 and its two-hundred day moving average is $63.36. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm has a market capitalization of $9.84 billion, a PE ratio of -39.02 and a beta of 4.00.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Named to TIME’s 2026 list and expanded clinical reach via a multi‑year collaboration with Keck/USC — boosts brand credibility, supports commercial adoption of Tempus’ AI precision‑medicine tools and expands addressable clinical volume (coverage cites TIME recognition and the Keck Medicine partnership). TIME recognition article Keck partnership article
• Positive Sentiment: Investor‑day visibility and bullish coverage — upcoming Investor Day (management roadmap) and fresh bull writeups may attract momentum buyers and reduce execution uncertainty if management delivers concrete commercialization milestones. Investor day / bull case coverage
• Neutral Sentiment: CEO Eric Lefkofsky sold 166,250 shares under a pre‑arranged Rule 10b5‑1 plan — provides liquidity/estate planning context but can be interpreted variably by the market; sale was disclosed in an SEC filing. SEC Form 4 disclosure
• Neutral Sentiment: Analyst/valuation mix — some firms trimmed fair‑value slightly and note the recent rally may be a short‑term bounce; coverage is polarized (buy/hold/sell), so flows depend on upcoming execution/metrics. Analyst narrative article
• Negative Sentiment: Class action litigation over genetic data collection in an acquisition — proposed suits raise legal, compliance and remediation cost risk that can pressure sentiment until resolved. Class action article
• Negative Sentiment: Peer comparisons favor Illumina (ILMN) on valuation and earnings outlook — could divert institutional allocation away from TEM if investors prefer a more established genomics exposure. Peer comparison article

Wall Street Analyst Weigh In

TEM has been the topic of several analyst reports. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Wednesday, March 11th. Morgan Stanley lowered their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Finally, HC Wainwright raised their price target on Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $71.36.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the business. JPL Wealth Management LLC acquired a new stake in Tempus AI in the third quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI in the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI in the third quarter worth about $38,000. Whittier Trust Co. boosted its holdings in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares in the last quarter. Finally, Lodestone Wealth Management LLC acquired a new stake in Tempus AI in the fourth quarter worth about $42,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.